investors
Invizyne IPO comments by CEO Michael Heltzen
Today's Nasdaq IPO marks new era of biomanufacturing - pioneered by Invizyne's breakthrough...
investors
Dr. Lalonde: From two years and 25 scientists to a few...
Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months "When I...
investors
Dr. Lalonde: Invizyne [...] helps the sustainability of...
"Invizyne is taking what nature has done and [...] putting things in a manufacturing format so we...
investors
NREL (DoE): What Invizyne is working on is a game changer
Yannick Bomble, PhD, Group Research Manager III-Biological Science at NREL (DoE), states: "What...
investors
Interview: NREL (DoE) working with Invizyne
NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project -...
investors
Commercializing Invizyne’s cell-free platform - fireside...
Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice...
investors
Invizyne IPO - KOL Call with Dr. James J. Lalonde (July...
MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a...
investors
Invizyne presented by Michael Heltzen & Tyler Korman
In this video, CEO of Invizyne, Michael Heltzen - and VP of Research, Tyler Korman, PhD -...
investors
Invizyne presented by Chris Marlett
In this video, CEO of MDB Capital Holdings, Chris Marlett, presents Invizyne. Invizyne is a...
interview
The story of Invizyne: Interview with Tyler Korman and...
In this video you'll hear Invizyne co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD...